Evaluation of Ocoxin-Viusid in Metastatic Colorectal Adenocarcinoma

ABSTRACT: The research product, registered as a nutritional supplement (Ocoxin, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin-Viusid on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin-Viusid it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.

DISEASE(S): Adenocarcinoma,Colorectal Neoplasm,Gastrointestinal Neoplasms,Intestinal Diseases,Gastrointestinal Disease,Digestive System Diseases,Neoplasms,Intestinal Disease,Gastrointestinal Diseases,Rectal Diseases,Colorectal Neoplasms,Digestive System Disease,Intestinal Neoplasms,Digestive System Neoplasms,Colonic Diseases,Digestive System Neoplasm

PROVIDER: 2275568 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR